Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Procyon Advisors LLC

Procyon Advisors LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,473 shares of the biopharmaceutical company’s stock after buying an additional 268 shares during the quarter. Procyon Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $3,343,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. Envestnet Portfolio Solutions Inc. purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $673,000. LPL Financial LLC grew its position in Regeneron Pharmaceuticals by 9.3% during the 3rd quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock worth $33,522,000 after purchasing an additional 3,479 shares in the last quarter. Mariner LLC boosted its stake in shares of Regeneron Pharmaceuticals by 2.9% during the 3rd quarter. Mariner LLC now owns 7,518 shares of the biopharmaceutical company’s stock valued at $6,187,000 after buying an additional 214 shares during the period. Stifel Financial Corp boosted its stake in shares of Regeneron Pharmaceuticals by 12.2% during the 3rd quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock valued at $25,537,000 after buying an additional 3,385 shares during the period. Finally, Federated Hermes Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 6.1% during the 3rd quarter. Federated Hermes Inc. now owns 2,796 shares of the biopharmaceutical company’s stock valued at $2,301,000 after buying an additional 160 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 756 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total value of $802,872.00. Following the sale, the director now owns 1,382 shares of the company’s stock, valued at $1,467,684. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,172 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total value of $1,142,535.92. Following the transaction, the director now directly owns 1,382 shares in the company, valued at $1,347,256.52. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Bonnie L. Bassler sold 756 shares of the business’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the completion of the transaction, the director now owns 1,382 shares in the company, valued at $1,467,684. The disclosure for this sale can be found here. Insiders have sold a total of 61,971 shares of company stock valued at $61,217,654 over the last quarter. 7.48% of the stock is owned by company insiders.

Analysts Set New Price Targets

REGN has been the subject of a number of research reports. Morgan Stanley lifted their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. Cantor Fitzgerald reissued a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. Royal Bank of Canada reissued an “outperform” rating and set a $1,229.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday. Finally, Bank of America lifted their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,015.91.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded down $18.30 on Thursday, hitting $1,050.86. 507,676 shares of the company were exchanged, compared to its average volume of 478,032. The company’s 50 day moving average price is $978.05 and its two-hundred day moving average price is $948.28. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $1,081.17. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The firm has a market capitalization of $115.79 billion, a price-to-earnings ratio of 31.17, a PEG ratio of 2.21 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The business had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.